Close

Professor Andrew Briggs

BSc (Hons) MSc DPhil

Professor

LSHTM
15-17 Tavistock Place
London
WC1H 9SH
United Kingdom

Professor of Health Economics at the London School of Hygiene & Tropical Medicine, and co-Director of the Global Health Economics Centre at the school, along with Anna Vassall and Mark Jit.  I  previously held the William R Lindsay Chair in Health Economics at the University of Glasgow.  Following a sabbatical at Memorial Sloan Kettering Cancer Center, New York in 2016/17, I remain a Visiting Investigator, collaborating with Dr Peter Bach on value frameworks for oncology medications.

I have  co-authored two textbooks, one published by OUP entitled Decision Modelling for Health Economic Evaluation, and the other published by Wiley entitled Statistical Methods for Cost-Effectiveness Analysis.

I am also Series Editor for OUP's Handbooks in Health Economic Evaluation series.

A link to my GooGle Scholar page: https://bit.ly/GS-briggs

Affiliations

Department of Health Services Research and Policy
Faculty of Public Health and Policy

Centres

Centre for Statistical Methodology
Global Health Economics Centre

Teaching

Our highly successful Foundations and Advanced Decision Modelling for Health Economic Evaluation courses have been developed for online delivery and include, as a new element for 2021, the ability to follow the practical exercises in the statistical package R as well as in Excel.

For full details and to book a place on the upcoming courses in May and June 2022, please visit the course website.

Research

My main methodological focus of research has been health economic evaluation, particularly statistical methods for cost-effectiveness analysis.  This includes statistical methods for estimation of parameters for cost-effectiveness models as well as statistical analysis of cost-effectiveness alongside clinical trials.  I have a more general interest in epidemiological methods, in particular the use of prognostic scoring methods for predicting health outcomes and the relationship with heterogeneity in cost-effectiveness analysis.

Research Area
Decision analysis
Economic evaluation
Randomised controlled trials
Discipline
Health economics
Country
United Kingdom
United States of America
South Africa
Region
European Union
North America
Sub-Saharan Africa (all income levels)

Selected Publications

Challenges for decision-makers when assessing within-class comparative effectiveness: the case of anticoagulation therapy for atrial fibrillation.
Briggs A; Howarth A; Davies S; Schneider J; Spentzouris G; Mughal F; Fuat A; Fay M
2022
Journal of comparative effectiveness research
Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS).
Cotton S; Devereux G; Abbas H; Briggs A; Campbell K; Chaudhuri R; Choudhury G; Dawson D; De Soyza A; Fielding S
2022
Trials
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations
Husereau D; Drummond M; Augustovski F; de Bekker-Grob E; Briggs AH; Carswell C; Caulley L; Chaiyakunapruk N; Greenberg D; Loder E
2022
Health Policy OPEN
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.
Husereau D; Drummond M; Augustovski F; de Bekker-Grob E; Briggs AH; Carswell C; Caulley L; Chaiyakunapruk N; Greenberg D; Loder E
2022
The European journal of health economics : HEPAC : health economics in prevention and care
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.
Husereau D; Drummond M; Augustovski F; de Bekker-Grob E; Briggs AH; Carswell C; Caulley L; Chaiyakunapruk N; Greenberg D; Loder E
2022
Journal of managed care & specialty pharmacy
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.
Husereau D; Drummond M; Augustovski F; de Bekker-Grob E; Briggs AH; Carswell C; Caulley L; Chaiyakunapruk N; Greenberg D; Loder E
2022
Clinical therapeutics
Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease.
Kohli-Lynch CN; Lewsey J; Boyd KA; French DD; Jordan N; Moran AE; Sattar N; Preiss D; Briggs AH
2022
Circulation
Modeling Chronic Kidney Disease in Type 2 Diabetes Mellitus: A Systematic Literature Review of Models, Data Sources, and Derivation Cohorts.
Pöhlmann J; Bergenheim K; Garcia Sanchez J-J; Rao N; Briggs A; Pollock RF
2022
Diabetes therapy : research, treatment and education of diabetes and related disorders
See more Publications